Compare YDES & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | YDES | KIO |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.9M | 455.8M |
| IPO Year | 2024 | 2011 |
| Metric | YDES | KIO |
|---|---|---|
| Price | $5.51 | $9.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 99.8K | ★ 345.6K |
| Earning Date | 08-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $9.70 |
| 52 Week High | $15.72 | $11.82 |
| Indicator | YDES | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 43.29 |
| Support Level | $4.69 | $9.76 |
| Resistance Level | $8.60 | $11.22 |
| Average True Range (ATR) | 0.81 | 0.14 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 21.92 | 37.98 |
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.